nodes	percent_of_prediction	percent_of_DWPC	metapath
Amcinonide—NR3C1—polycystic ovary syndrome	0.785	1	CbGaD
Amcinonide—ANXA1—Prostaglandin Synthesis and Regulation—PTGER3—polycystic ovary syndrome	0.008	0.0607	CbGpPWpGaD
Amcinonide—NR3C1—urine—polycystic ovary syndrome	0.00768	0.106	CbGeAlD
Amcinonide—ANXA1—embryo—polycystic ovary syndrome	0.00715	0.0983	CbGeAlD
Amcinonide—ANXA1—adrenal cortex—polycystic ovary syndrome	0.00586	0.0806	CbGeAlD
Amcinonide—ANXA1—endometrium—polycystic ovary syndrome	0.00523	0.0719	CbGeAlD
Amcinonide—ANXA1—uterus—polycystic ovary syndrome	0.00482	0.0663	CbGeAlD
Amcinonide—ANXA1—pituitary gland—polycystic ovary syndrome	0.00473	0.0651	CbGeAlD
Amcinonide—ANXA1—adipose tissue—polycystic ovary syndrome	0.00471	0.0648	CbGeAlD
Amcinonide—ANXA1—adrenal gland—polycystic ovary syndrome	0.00423	0.0582	CbGeAlD
Amcinonide—ANXA1—female gonad—polycystic ovary syndrome	0.00394	0.0542	CbGeAlD
Amcinonide—ANXA1—Prostaglandin Synthesis and Regulation—CYP11A1—polycystic ovary syndrome	0.00393	0.0298	CbGpPWpGaD
Amcinonide—ANXA1—vagina—polycystic ovary syndrome	0.00392	0.0539	CbGeAlD
Amcinonide—ANXA1—endocrine gland—polycystic ovary syndrome	0.00367	0.0504	CbGeAlD
Amcinonide—ANXA1—Prostaglandin Synthesis and Regulation—PRL—polycystic ovary syndrome	0.00294	0.0223	CbGpPWpGaD
Amcinonide—NR3C1—embryo—polycystic ovary syndrome	0.00248	0.0342	CbGeAlD
Amcinonide—ANXA1—Peptide ligand-binding receptors—NPB—polycystic ovary syndrome	0.00219	0.0166	CbGpPWpGaD
Amcinonide—NR3C1—adrenal cortex—polycystic ovary syndrome	0.00203	0.028	CbGeAlD
Amcinonide—ANXA1—G alpha (i) signalling events—NPB—polycystic ovary syndrome	0.00185	0.014	CbGpPWpGaD
Amcinonide—NR3C1—endometrium—polycystic ovary syndrome	0.00182	0.025	CbGeAlD
Amcinonide—ANXA1—G alpha (q) signalling events—PTAFR—polycystic ovary syndrome	0.00173	0.0131	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (q) signalling events—ADRA1D—polycystic ovary syndrome	0.00168	0.0128	CbGpPWpGaD
Amcinonide—NR3C1—uterus—polycystic ovary syndrome	0.00167	0.023	CbGeAlD
Amcinonide—NR3C1—pituitary gland—polycystic ovary syndrome	0.00164	0.0226	CbGeAlD
Amcinonide—NR3C1—adipose tissue—polycystic ovary syndrome	0.00164	0.0225	CbGeAlD
Amcinonide—ANXA1—G alpha (q) signalling events—ADRA1B—polycystic ovary syndrome	0.00164	0.0124	CbGpPWpGaD
Amcinonide—NR3C1—Transcription factor regulation in adipogenesis—INSR—polycystic ovary syndrome	0.00158	0.012	CbGpPWpGaD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—PTAFR—polycystic ovary syndrome	0.00155	0.0118	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—PTGER3—polycystic ovary syndrome	0.00154	0.0117	CbGpPWpGaD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1D—polycystic ovary syndrome	0.0015	0.0114	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—NPB—polycystic ovary syndrome	0.00147	0.0111	CbGpPWpGaD
Amcinonide—NR3C1—adrenal gland—polycystic ovary syndrome	0.00147	0.0202	CbGeAlD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1B—polycystic ovary syndrome	0.00146	0.0111	CbGpPWpGaD
Amcinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—polycystic ovary syndrome	0.00146	0.0111	CbGpPWpGaD
Amcinonide—NR3C1—female gonad—polycystic ovary syndrome	0.00137	0.0188	CbGeAlD
Amcinonide—NR3C1—vagina—polycystic ovary syndrome	0.00136	0.0187	CbGeAlD
Amcinonide—NR3C1—Transcription factor regulation in adipogenesis—ADIPOQ—polycystic ovary syndrome	0.00132	0.01	CbGpPWpGaD
Amcinonide—NR3C1—endocrine gland—polycystic ovary syndrome	0.00127	0.0175	CbGeAlD
Amcinonide—NR3C1—Transcription factor regulation in adipogenesis—SLC2A4—polycystic ovary syndrome	0.00125	0.00946	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (q) signalling events—ADRA1A—polycystic ovary syndrome	0.00124	0.0094	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.00123	0.0093	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.00123	0.0093	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—FST—polycystic ovary syndrome	0.00119	0.00901	CbGpPWpGaD
Amcinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—GNAS—polycystic ovary syndrome	0.00118	0.00892	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (q) signalling events—GNRH1—polycystic ovary syndrome	0.00115	0.00874	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.00115	0.0087	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—NPB—polycystic ovary syndrome	0.00112	0.00849	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.00111	0.00845	CbGpPWpGaD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1A—polycystic ovary syndrome	0.00111	0.00841	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.00108	0.00822	CbGpPWpGaD
Amcinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NAMPT—polycystic ovary syndrome	0.00106	0.00807	CbGpPWpGaD
Amcinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—IGFBP1—polycystic ovary syndrome	0.00106	0.00804	CbGpPWpGaD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—polycystic ovary syndrome	0.00103	0.00782	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—LIFR—polycystic ovary syndrome	0.000998	0.00757	CbGpPWpGaD
Amcinonide—ANXA1—Spinal Cord Injury—NGFR—polycystic ovary syndrome	0.000991	0.00751	CbGpPWpGaD
Amcinonide—NR3C1—Nuclear Receptors—PGR—polycystic ovary syndrome	0.000947	0.00718	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.000934	0.00708	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.000934	0.00708	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.000898	0.00681	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—ATF1—polycystic ovary syndrome	0.000881	0.00668	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—MTNR1B—polycystic ovary syndrome	0.000878	0.00666	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.000874	0.00663	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.000848	0.00643	CbGpPWpGaD
Amcinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—polycystic ovary syndrome	0.000842	0.00639	CbGpPWpGaD
Amcinonide—NR3C1—Transcription factor regulation in adipogenesis—IRS2—polycystic ovary syndrome	0.000838	0.00636	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.000825	0.00626	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—TOP2A—polycystic ovary syndrome	0.000823	0.00625	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.000821	0.00623	CbGpPWpGaD
Amcinonide—NR3C1—Transcription factor regulation in adipogenesis—LEP—polycystic ovary syndrome	0.00082	0.00622	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—TAB1—polycystic ovary syndrome	0.000813	0.00617	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—LIF—polycystic ovary syndrome	0.000813	0.00617	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—RETN—polycystic ovary syndrome	0.000813	0.00617	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—CYP19A1—polycystic ovary syndrome	0.000794	0.00603	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00079	0.006	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.000781	0.00592	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.000778	0.00591	CbGpPWpGaD
Amcinonide—NR3C1—Circadian Clock—NAMPT—polycystic ovary syndrome	0.000775	0.00588	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—AR—polycystic ovary syndrome	0.000773	0.00586	CbGpPWpGaD
Amcinonide—ANXA1—Peptide ligand-binding receptors—GHRL—polycystic ovary syndrome	0.000769	0.00583	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.000763	0.00579	CbGpPWpGaD
Amcinonide—NR3C1—Nuclear Receptor transcription pathway—PGR—polycystic ovary syndrome	0.000748	0.00568	CbGpPWpGaD
Amcinonide—NR3C1—Nuclear Receptors—AR—polycystic ovary syndrome	0.000736	0.00559	CbGpPWpGaD
Amcinonide—NR3C1—Transcription factor regulation in adipogenesis—IRS1—polycystic ovary syndrome	0.000731	0.00555	CbGpPWpGaD
Amcinonide—NR3C1—Transcription factor regulation in adipogenesis—PPARG—polycystic ovary syndrome	0.000714	0.00542	CbGpPWpGaD
Amcinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—polycystic ovary syndrome	0.000711	0.0054	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.000698	0.0053	CbGpPWpGaD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.000696	0.00528	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.000684	0.00519	CbGpPWpGaD
Amcinonide—ANXA1—Spinal Cord Injury—LEP—polycystic ovary syndrome	0.000677	0.00513	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—BAX—polycystic ovary syndrome	0.000658	0.00499	CbGpPWpGaD
Amcinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—polycystic ovary syndrome	0.000658	0.00499	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—AR—polycystic ovary syndrome	0.00064	0.00486	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.000632	0.0048	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.000625	0.00474	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.000602	0.00457	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—LHB—polycystic ovary syndrome	0.000595	0.00451	CbGpPWpGaD
Amcinonide—NR3C1—Nuclear Receptor transcription pathway—AR—polycystic ovary syndrome	0.000582	0.00441	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.000581	0.00441	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—NPB—polycystic ovary syndrome	0.000574	0.00436	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.000572	0.00434	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—ZNF205—polycystic ovary syndrome	0.000565	0.00429	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—ZNF430—polycystic ovary syndrome	0.000565	0.00429	CbGpPWpGaD
Amcinonide—NR3C1—Regulation of Androgen receptor activity—AR—polycystic ovary syndrome	0.000564	0.00428	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00056	0.00425	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00056	0.00425	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.000557	0.00423	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—BAX—polycystic ovary syndrome	0.000545	0.00414	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.000532	0.00403	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.000528	0.004	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.000528	0.004	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.000519	0.00394	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.000516	0.00391	CbGpPWpGaD
Amcinonide—NR3C1—AP-1 transcription factor network—TH—polycystic ovary syndrome	0.000508	0.00385	CbGpPWpGaD
Amcinonide—NR3C1—AP-1 transcription factor network—TCF7L2—polycystic ovary syndrome	0.000502	0.00381	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—GNAS—polycystic ovary syndrome	0.000498	0.00378	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—IRS1—polycystic ovary syndrome	0.000496	0.00376	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.000494	0.00374	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.000479	0.00364	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.000479	0.00364	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.000479	0.00364	CbGpPWpGaD
Amcinonide—NR3C1—Circadian Clock—NCOR1—polycystic ovary syndrome	0.000479	0.00363	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.000466	0.00354	CbGpPWpGaD
Amcinonide—NR3C1—Nuclear Receptors—PPARG—polycystic ovary syndrome	0.000461	0.0035	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.000448	0.0034	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.000435	0.0033	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.000427	0.00324	CbGpPWpGaD
Amcinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—SERPINE1—polycystic ovary syndrome	0.000425	0.00322	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.000424	0.00322	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.000423	0.00321	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—RUNX3—polycystic ovary syndrome	0.000421	0.00319	CbGpPWpGaD
Amcinonide—NR3C1—Glucocorticoid receptor regulatory network—PRL—polycystic ovary syndrome	0.000415	0.00315	CbGpPWpGaD
Amcinonide—Difluprednate—NR3C1—polycystic ovary syndrome	0.000406	0.0389	CrCbGaD
Amcinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—INS—polycystic ovary syndrome	0.000402	0.00305	CbGpPWpGaD
Amcinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AR—polycystic ovary syndrome	0.000402	0.00305	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—BCL2—polycystic ovary syndrome	0.000401	0.00304	CbGpPWpGaD
Amcinonide—ANXA1—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.000397	0.00301	CbGpPWpGaD
Amcinonide—Prednicarbate—NR3C1—polycystic ovary syndrome	0.000393	0.0377	CrCbGaD
Amcinonide—ANXA1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.000393	0.00298	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—NAMPT—polycystic ovary syndrome	0.000389	0.00295	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000388	0.00294	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.000386	0.00293	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.000385	0.00292	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	0.00038	0.00289	CbGpPWpGaD
Amcinonide—Desonide—NR3C1—polycystic ovary syndrome	0.000372	0.0357	CrCbGaD
Amcinonide—Diflorasone—NR3C1—polycystic ovary syndrome	0.000372	0.0357	CrCbGaD
Amcinonide—NR3C1—Adipogenesis—LMNA—polycystic ovary syndrome	0.000369	0.0028	CbGpPWpGaD
Amcinonide—NR3C1—Nuclear Receptor transcription pathway—PPARG—polycystic ovary syndrome	0.000365	0.00277	CbGpPWpGaD
Amcinonide—Desoximetasone—NR3C1—polycystic ovary syndrome	0.000363	0.0348	CrCbGaD
Amcinonide—Loteprednol—NR3C1—polycystic ovary syndrome	0.000359	0.0344	CrCbGaD
Amcinonide—Fludrocortisone—AR—polycystic ovary syndrome	0.000354	0.0339	CrCbGaD
Amcinonide—ANXA1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.000353	0.00268	CbGpPWpGaD
Amcinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—polycystic ovary syndrome	0.000351	0.00267	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.000351	0.00266	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00034	0.00258	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—NPB—polycystic ovary syndrome	0.000339	0.00257	CbGpPWpGaD
Amcinonide—NR3C1—Glucocorticoid receptor regulatory network—BAX—polycystic ovary syndrome	0.000339	0.00257	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.000336	0.00255	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.000335	0.00254	CbGpPWpGaD
Amcinonide—Fluoxymesterone—SHBG—polycystic ovary syndrome	0.000333	0.0319	CrCbGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	0.000332	0.00252	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.000328	0.00249	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.000325	0.00247	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000321	0.00243	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—ADIPOQ—polycystic ovary syndrome	0.000319	0.00242	CbGpPWpGaD
Amcinonide—Flurandrenolide—NR3C1—polycystic ovary syndrome	0.000318	0.0305	CrCbGaD
Amcinonide—ANXA1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.000315	0.00239	CbGpPWpGaD
Amcinonide—Flumethasone Pivalate—NR3C1—polycystic ovary syndrome	0.000313	0.03	CrCbGaD
Amcinonide—NR3C1—Generic Transcription Pathway—TEAD2—polycystic ovary syndrome	0.00031	0.00235	CbGpPWpGaD
Amcinonide—NR3C1—Circadian Clock—SERPINE1—polycystic ovary syndrome	0.000309	0.00235	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000309	0.00234	CbGpPWpGaD
Amcinonide—Halobetasol Propionate—NR3C1—polycystic ovary syndrome	0.000308	0.0295	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000307	0.00233	CbGpPWpGaD
Amcinonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—polycystic ovary syndrome	0.000306	0.00232	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000305	0.00232	CbGpPWpGaD
Amcinonide—Fluticasone Propionate—PGR—polycystic ovary syndrome	0.000303	0.0291	CrCbGaD
Amcinonide—Cortisone acetate—NR3C1—polycystic ovary syndrome	0.000303	0.029	CrCbGaD
Amcinonide—ANXA1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000301	0.00229	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—SLC2A4—polycystic ovary syndrome	0.000301	0.00228	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.0003	0.00228	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—VEGFA—polycystic ovary syndrome	0.0003	0.00228	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000298	0.00226	CbGpPWpGaD
Amcinonide—Fluoxymesterone—AR—polycystic ovary syndrome	0.000292	0.028	CrCbGaD
Amcinonide—ANXA1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000286	0.00217	CbGpPWpGaD
Amcinonide—Budesonide—NR3C1—polycystic ovary syndrome	0.000286	0.0274	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000283	0.00215	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000283	0.00215	CbGpPWpGaD
Amcinonide—Fluticasone furoate—NR3C1—polycystic ovary syndrome	0.00028	0.0269	CrCbGaD
Amcinonide—Betamethasone—PGR—polycystic ovary syndrome	0.000278	0.0266	CrCbGaD
Amcinonide—ANXA1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000273	0.00207	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—ZNF205—polycystic ovary syndrome	0.000272	0.00206	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—ZNF430—polycystic ovary syndrome	0.000272	0.00206	CbGpPWpGaD
Amcinonide—Mometasone—NR3C1—polycystic ovary syndrome	0.000272	0.0261	CrCbGaD
Amcinonide—Rimexolone—NR3C1—polycystic ovary syndrome	0.000269	0.0258	CrCbGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—TH—polycystic ovary syndrome	0.000267	0.00203	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000266	0.00202	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000265	0.00201	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000257	0.00195	CbGpPWpGaD
Amcinonide—Beclomethasone—NR3C1—polycystic ovary syndrome	0.000254	0.0243	CrCbGaD
Amcinonide—Fluocinonide—NR3C1—polycystic ovary syndrome	0.000254	0.0243	CrCbGaD
Amcinonide—ANXA1—Spinal Cord Injury—IL6—polycystic ovary syndrome	0.000253	0.00192	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00025	0.0019	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	0.000249	0.00189	CbGpPWpGaD
Amcinonide—Fluocinolone Acetonide—NR3C1—polycystic ovary syndrome	0.000246	0.0236	CrCbGaD
Amcinonide—NR3C1—Glucocorticoid receptor regulatory network—POMC—polycystic ovary syndrome	0.000246	0.00187	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000244	0.00185	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—NCOR1—polycystic ovary syndrome	0.000241	0.00183	CbGpPWpGaD
Amcinonide—Clobetasol propionate—NR3C1—polycystic ovary syndrome	0.00024	0.023	CrCbGaD
Amcinonide—Fludrocortisone—NR3C1—polycystic ovary syndrome	0.00024	0.023	CrCbGaD
Amcinonide—Flunisolide—NR3C1—polycystic ovary syndrome	0.00024	0.023	CrCbGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—AR—polycystic ovary syndrome	0.000238	0.0018	CbGpPWpGaD
Amcinonide—Ciclesonide—NR3C1—polycystic ovary syndrome	0.000233	0.0223	CrCbGaD
Amcinonide—NR3C1—Gene Expression—ADARB1—polycystic ovary syndrome	0.000231	0.00176	CbGpPWpGaD
Amcinonide—Fluorometholone—NR3C1—polycystic ovary syndrome	0.000231	0.0222	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000228	0.00173	CbGpPWpGaD
Amcinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SERPINE1—polycystic ovary syndrome	0.000227	0.00172	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000222	0.00168	CbGpPWpGaD
Amcinonide—Clobetasol propionate—CYP1A1—polycystic ovary syndrome	0.000218	0.0209	CrCbGaD
Amcinonide—Dexamethasone—CYP17A1—polycystic ovary syndrome	0.000218	0.0209	CrCbGaD
Amcinonide—Dexamethasone—CYP11A1—polycystic ovary syndrome	0.000214	0.0205	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000207	0.00157	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000203	0.00154	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—IRS2—polycystic ovary syndrome	0.000202	0.00153	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000201	0.00153	CbGpPWpGaD
Amcinonide—Fluoxymesterone—NR3C1—polycystic ovary syndrome	0.000198	0.019	CrCbGaD
Amcinonide—NR3C1—Adipogenesis—LEP—polycystic ovary syndrome	0.000198	0.0015	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000195	0.00148	CbGpPWpGaD
Amcinonide—Betamethasone—CYP19A1—polycystic ovary syndrome	0.000191	0.0183	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.00019	0.00144	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—LSM5—polycystic ovary syndrome	0.000189	0.00143	CbGpPWpGaD
Amcinonide—Triamcinolone—NR3C1—polycystic ovary syndrome	0.000188	0.0181	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—FST—polycystic ovary syndrome	0.000185	0.0014	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000184	0.00139	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000182	0.00138	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—LHB—polycystic ovary syndrome	0.00018	0.00137	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—IRS1—polycystic ovary syndrome	0.000177	0.00134	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000176	0.00134	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—SAP30L—polycystic ovary syndrome	0.000175	0.00133	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—PPARG—polycystic ovary syndrome	0.000172	0.00131	CbGpPWpGaD
Amcinonide—Prednisone—NR3C1—polycystic ovary syndrome	0.000171	0.0164	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000171	0.00129	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.00017	0.00129	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—INS—polycystic ovary syndrome	0.000169	0.00128	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000169	0.00128	CbGpPWpGaD
Amcinonide—Fluticasone Propionate—NR3C1—polycystic ovary syndrome	0.000169	0.0161	CrCbGaD
Amcinonide—ANXA1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000167	0.00127	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—IGF1—polycystic ovary syndrome	0.000164	0.00124	CbGpPWpGaD
Amcinonide—Dexamethasone—PGR—polycystic ovary syndrome	0.000162	0.0155	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000161	0.00122	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000158	0.0012	CbGpPWpGaD
Amcinonide—Prednisolone—NR3C1—polycystic ovary syndrome	0.000158	0.0151	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000157	0.00119	CbGpPWpGaD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000156	0.00119	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—SERPINE1—polycystic ovary syndrome	0.000155	0.00118	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000155	0.00117	CbGpPWpGaD
Amcinonide—Betamethasone—NR3C1—polycystic ovary syndrome	0.000154	0.0148	CrCbGaD
Amcinonide—NR3C1—Gene Expression—TEAD2—polycystic ovary syndrome	0.000149	0.00113	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—YAP1—polycystic ovary syndrome	0.000148	0.00112	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000147	0.00111	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000145	0.0011	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000138	0.00105	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000131	0.000997	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000129	0.000981	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—PGR—polycystic ovary syndrome	0.000129	0.00098	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000128	0.000971	CbGpPWpGaD
Amcinonide—NR3C1—AP-1 transcription factor network—IL6—polycystic ovary syndrome	0.000121	0.00092	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000119	0.000903	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000119	0.000903	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000115	0.00087	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000114	0.000861	CbGpPWpGaD
Amcinonide—Dexamethasone—CYP19A1—polycystic ovary syndrome	0.000111	0.0106	CrCbGaD
Amcinonide—ANXA1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000111	0.00084	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.00011	0.000836	CbGpPWpGaD
Amcinonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—polycystic ovary syndrome	0.000107	0.000811	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—RPL37A—polycystic ovary syndrome	0.000106	0.000806	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000105	0.000795	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000104	0.00079	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000104	0.000788	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—AR—polycystic ovary syndrome	0.000101	0.000763	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.0001	0.000759	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.85e-05	0.000747	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	9.23e-05	0.000701	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—GNAS—polycystic ovary syndrome	9.13e-05	0.000693	CbGpPWpGaD
Amcinonide—Dexamethasone—NR3C1—polycystic ovary syndrome	8.98e-05	0.00861	CrCbGaD
Amcinonide—NR3C1—Generic Transcription Pathway—NCOR1—polycystic ovary syndrome	8.79e-05	0.000666	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.7e-05	0.00066	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—NRG1—polycystic ovary syndrome	8.54e-05	0.000648	CbGpPWpGaD
Amcinonide—Dexamethasone—CYP1A1—polycystic ovary syndrome	8.15e-05	0.00782	CrCbGaD
Amcinonide—NR3C1—Adipogenesis—IL6—polycystic ovary syndrome	7.39e-05	0.000561	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—IRS2—polycystic ovary syndrome	7.32e-05	0.000555	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—LEP—polycystic ovary syndrome	7.16e-05	0.000543	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—YAP1—polycystic ovary syndrome	7.13e-05	0.000541	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—IRS1—polycystic ovary syndrome	6.39e-05	0.000485	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	6.39e-05	0.000485	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—PPARG—polycystic ovary syndrome	6.3e-05	0.000478	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—TNRC6B—polycystic ovary syndrome	6.29e-05	0.000477	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—PGR—polycystic ovary syndrome	6.22e-05	0.000472	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—POMC—polycystic ovary syndrome	6.15e-05	0.000467	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—INS—polycystic ovary syndrome	6.12e-05	0.000464	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—IGF1—polycystic ovary syndrome	5.92e-05	0.000449	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—AKT2—polycystic ovary syndrome	5.91e-05	0.000449	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—SERPINE1—polycystic ovary syndrome	5.67e-05	0.00043	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.62e-05	0.000426	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—AR—polycystic ovary syndrome	4.84e-05	0.000367	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.52e-05	0.000343	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—NCOR1—polycystic ovary syndrome	4.23e-05	0.000321	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.86e-05	0.000293	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—PPARG—polycystic ovary syndrome	3.03e-05	0.00023	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—SERPINE1—polycystic ovary syndrome	2.73e-05	0.000207	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—IL6—polycystic ovary syndrome	2.67e-05	0.000203	CbGpPWpGaD
